Clinical trials: Bronchoalveolar Lavage
Infections, Bacterial
To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944
Antimicrobial penetration can be assessed through evaluation of antimicrobial concentrations in various lung compartments, including bronchial mucosal tissue, epithelial lining fluid (ELF), and alveolar macrophages (AM).
- Trial name
- NCT01934205
- Testing
- GSK2140944 (Single dose), GSK2140944 (Multiple dose)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.
- Trial name
- NCT04868292
- Testing
- SPR206
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Community-acquired Infection
An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the…
- Trial name
- NCT01267968
- Testing
- GSK2251052
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
To evaluate the effect of MEDI-528 in adults with atopic asthma.
- Trial name
- NCT00483041
- Testing
- MEDI528 9 mg/kg
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Meconium Aspiration
Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
- Trial name
- NCT00004500
- Testing
- Lucinactant, Standard Care
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Windtree Therapeutics
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18.
- Trial name
- NCT06431776
- Testing
- Molgramostim
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Savara Inc.
Pharmacokinetics Study on Healthy Volunteers Adults
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
This is an open-label, non-randomized, single-center, repeated i.v. doses, Phase 1 trial to evaluate the pharmacokinetics, safety, and tolerability of a combination of MEM-ANT3310 in healthy adult female and male participants who…
- Trial name
- NCT06916156
- Testing
- ANT3310, Meropenem
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Antabio
Atelectasis, Bronchoscopy
Evaluation of BAL Procedure With Ambu aScope 3 Large in Patients in an ICU Setting
An Investigation to determine the single-use scope's ability to suction secretion from the lungs to resolve the collapse of the lung.
- Trial name
- NCT03581474
- Testing
- Bronchoscopic procedure
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ambu A/S
Healthy
Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects
This is a Phase 1, multiple dose, open-label pharmacokinetic study conducted in healthy adult male and female subjects to determine and compare plasma, epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of…
- Trial name
- NCT03303924
- Testing
- ETX2514 and sulbactam
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Entasis Therapeutics
Healthy Subjects
A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)
Lavage fluid (BAL) is inserted into a lung lobe using a flexible bronchoscope. The fluid is aspirated out to remove any remaining TI. It's performed twice at specific time points in 12 healthy volunteers.
- Trial name
- NCT00757367
- Testing
- TI Inhalation Powder
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Alpha1-antitrypsin Deficiency
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation…
- Trial name
- NCT02525861
- Testing
- GLASSIA
- Where
- 18 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Baxalta now part of Shire